Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock
CELEBRATION, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (Nasdaq:ZVRA), a rare disease therapeutics company (“Zevra”), today announced the pricing of an underwritten public offering of 9,230,770 shares of its common stock at an offering price of $6.50 per share, for total gross proceeds of approximately $60.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Zevra. All of the common stock is being offered by Zevra. The offering is expected to close on August 12, 2024, subject to customary closing conditions. In addition, Zevra has granted the underwriters a 30-day option to purchase up to an additional 1,384,615 shares of its common stock at the public offering price, less underwriting discounts and commissions.